Study design for development of novel safety biomarkers of drug-induced liver injury by the translational safety biomarker pipeline (TransBioLine) consortium: a study protocol for a nested case–control study

Grove, Jane I.; Stephens, Camilla; Lucena, M. Isabel; Andrade, Raúl J.; Weber, Sabine; Gerbes, Alexander; Bjornsson, Einar S.; Stirnimann, Guido; Daly, Ann K.; Hackl, Matthias; Khamina-Kotisch, Kseniya; Marin, Jose J. G.; Monte, Maria J.; Paciga, Sara A.; Lingaya, Melanie; Forootan, Shiva S.; Goldring, Christopher E. P.; Poetz, Oliver; Lombaard, Rudolf; Stege, Alexandra; Bjorrnsson, Helgi K.; Robles-Diaz, Mercedes; Li, Dingzhou; Tran, Thi Dong Binh; Ramaiah, Shashi K.; Samodelov, Sophia L.; Kullak-Ublick, Gerd A.; Aithal, Guruprasad P.; on behalf of the TransBioLine consortium

Abstract

A lack of biomarkers that detect drug-induced liver injury (DILI) accurately continues to hinder early- and late-stage drug development and remains a challenge in clinical practice. The Innovative Medicines Initiative’s TransBioLine consortium comprising academic and industry partners is developing a prospective repository of deeply phenotyped cases and controls with biological samples during liver injury progression to facilitate biomarker discovery, evaluation, validation and qualification. In a nested case–control design, patients who meet one of these criteria, alanine transaminase (ALT) ≥ 5 × the upper limit of normal (ULN), alkaline phosphatase ≥ 2 × ULN or ALT ≥ 3 ULN with total bilirubin > 2 × ULN, are enrolled. After completed clinical investigations, Roussel Uclaf Causality Assessment and expert panel review are used to adjudicate episodes as DILI or alternative liver diseases (acute non-DILI controls). Two blood samples are taken: at recruitment and follow-up. Sample size is as follows: 300 cases of DILI and 130 acute non-DILI controls. Additional cross-sectional cohorts (1 visit) are as follows: Healthy volunteers (n = 120), controls with chronic alcohol-related or non-alcoholic fatty liver disease (n = 100 each) and patients with psoriasis or rheumatoid arthritis (n = 100, 50 treated with methotrexate) are enrolled. Candidate biomarkers prioritised for evaluation include osteopontin, glutamate dehydrogenase, cytokeratin-18 (full length and caspase cleaved), macrophage-colony-stimulating factor 1 receptor and high mobility group protein B1 as well as bile acids, sphingolipids and microRNAs. The TransBioLine project is enabling biomarker discovery and validation that could improve detection, diagnostic accuracy and prognostication of DILI in premarketing clinical trials and for clinical healthcare application.

Citation

Grove, J. I., Stephens, C., Lucena, M. I., Andrade, R. J., Weber, S., Gerbes, A., …on behalf of the TransBioLine consortium. (2023). Study design for development of novel safety biomarkers of drug-induced liver injury by the translational safety biomarker pipeline (TransBioLine) consortium: a study protocol for a nested case–control study. Diagnostic and Prognostic Research, 7, Article 18. https://doi.org/10.1186/s41512-023-00155-z

• Journal Article Type: Article
• Acceptance Date: Aug 8, 2023
• Online Publication Date: Sep 12, 2023
• Publication Date: 2023
• Deposit Date: Sep 12, 2023
• Publicly Available Date: Sep 28, 2023
• Journal: Diagnostic and Prognostic Research
• Print ISSN: 2397-7523
• Publisher: BioMed Central
• Peer Reviewed: Peer Reviewed
• Volume: 7
• Article Number: 18
• DOI: https://doi.org/10.1186/s41512-023-00155-z
• Keywords: Religious studies; Cultural Studies
• Public URL: https://nottingham-repository.worktribe.com/output/25277962
• Publisher URL: https://diagnprognres.biomedcentral.com/articles/10.1186/s41512-023-00155-z